Theriva biologics announces orphan medicinal product designation granted by the european commission to vcn-01 for the treatment of retinoblastoma

Rockville, md., oct. 16, 2024 (globe newswire) -- theriva biologics (nyse american: tovx), (“theriva” or the “company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the european commission has adopted the european medicines agency (ema) recommendation to grant orphan medicinal product designation to lead clinical candidate vcn-01, theriva's systemic, selective, stroma-degrading oncolytic adenovirus, for the treatment of retinoblastoma. the united states food and drug administration (fda) has previously granted orphan drug designation and rare pediatric disease designation to vcn-01 for the treatment of retinoblastoma.
TOVX Ratings Summary
TOVX Quant Ranking